What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
James L. Abbruzzese mainly investigates Internal medicine, Pancreatic cancer, Cancer research, Surgery and Cancer.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology and Oncology.
James L. Abbruzzese has researched Oncology in several fields, including Metformin and Confidence interval.
James L. Abbruzzese combines subjects such as Immunology, Pancreatic disease, Pancreas and Adenocarcinoma with his study of Pancreatic cancer.
His studies deal with areas such as Carcinogenesis, Transcription factor and Metastasis as well as Cancer research.
The various areas that James L. Abbruzzese examines in his Cancer study include Immunohistochemistry, Carcinoma, Pathology, Progressive disease and Diabetes mellitus.
His most cited work include:
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis (2220 citations)
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (939 citations)
- Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer (905 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Pancreatic cancer, Oncology, Cancer research and Cancer.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery.
His study in Pancreatic cancer is interdisciplinary in nature, drawing from both Endocrinology, Pancreatic disease, Pancreas, Pathology and Genotype.
His Oncology research incorporates themes from Clinical trial, Phases of clinical research, Colorectal cancer, Capecitabine and Hepatocellular carcinoma.
His Cancer research research includes elements of Carcinogenesis, Apoptosis, Protein kinase B and Metastasis.
His Adenocarcinoma research focuses on Pancreaticoduodenectomy and how it connects with Neoadjuvant therapy.
He most often published in these fields:
- Internal medicine (54.05%)
- Pancreatic cancer (42.05%)
- Oncology (32.66%)
What were the highlights of his more recent work (between 2011-2021)?
- Internal medicine (54.05%)
- Pancreatic cancer (42.05%)
- Oncology (32.66%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Pancreatic cancer, Oncology, Cancer research and Cancer.
The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine.
His work investigates the relationship between Pancreatic cancer and topics such as Pancreas that intersect with problems in Pancreatic Intraepithelial Neoplasia.
His Oncology research is multidisciplinary, incorporating elements of Chemotherapy, Hepatocellular carcinoma, Carcinoma, Biomarker and Survival analysis.
His Cancer research research focuses on subjects like KRAS, which are linked to FGF21 and Adipose tissue.
In Cancer, James L. Abbruzzese works on issues like Stage, which are connected to Lymph node.
Between 2011 and 2021, his most popular works were:
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators (335 citations)
- Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer (213 citations)
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed? (175 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
James L. Abbruzzese spends much of his time researching Internal medicine, Oncology, Pancreatic cancer, Adenocarcinoma and Neoadjuvant therapy.
His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine.
The Oncology study combines topics in areas such as Hepatocellular carcinoma, Clinical endpoint, Carcinoma and Phases of clinical research.
James L. Abbruzzese interconnects Diabetes mellitus, Pathology, Gemcitabine, Surgical oncology and Radiation therapy in the investigation of issues within Pancreatic cancer.
His Adenocarcinoma study integrates concerns from other disciplines, such as Surgery, Hypophosphatemia, Proto-oncogene tyrosine-protein kinase Src, Toxicity and Chemoradiotherapy.
His research integrates issues of Pancreaticoduodenectomy and Pancreatic ductal adenocarcinoma in his study of Neoadjuvant therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
